TKI-MKB research grant · Biotech
Laigo Bio awarded Health~Holland grant for cancer drug research
The TKI-MKB subsidy supports development of targeted protein degraders.
Laigo Bio announced a Health~Holland TKI-MKB grant on October 15, 2024, to advance its SureTACs technology with UMC Utrecht and the Oncode Institute. The award amount was not disclosed.
The project will optimise lead molecules and advance them towards development candidate nomination, preparing the targeted protein degradation programmes for further clinical development.
Use of funds
Optimize SureTAC molecules for cancer treatment
Advance lead molecules to development candidate nomination
Funding history
TKI-MKB research grant · This roundUndisclosed